BOSTON - Seaport Therapeutics, a clinical-stage biopharmaceutical company, has published new research demonstrating significant advancements in drug delivery through the lymphatic system using its ...

PureTech-founded Seaport Therapeutics has raised $225m in a Series ... Seaport plans to use the new funds to push forward its ...

PureTech Founded Entity Seaport Therapeutics Announces Publication of New Research Demonstrating Increased Lymphatic Transport with Glyph Platform ...

After emerging from the shadows with a $100 million Series A in April, Seaport Therapeutics has moved ... Seaport said the money would support a pipeline of improved neuropsychiatric drug ...

Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the ...

The team that brought you Karuna – recently sold to Bristol-Myers Squibb for $14 billion – has set up a neuropsychiatry-focused biotech called Seaport Therapeutics. Karuna co-founder Daphne ...

Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team ...

Seaport’s development plans for its pipeline of therapeutics for the treatment of depression, anxiety and other neuropsychiatric disorders, potential benefits to patients, the anticipated use of ...